What Is Testosterone Replacement Therapy

Testosterone replacement therapy (TRT) is the clinical administration of exogenous testosterone to individuals whose bodies produce insufficient amounts, a condition known as hypogonadism. It is delivered through intramuscular injections, transdermal gels or patches, subcutaneous pellets, or nasal preparations. The objective is to restore circulating testosterone to a physiological range and relieve the symptoms associated with deficiency.

Testosterone influences far more than reproductive function. It plays direct roles in maintaining skeletal muscle mass, bone mineral density, red blood cell production, fat distribution, mood regulation, and cognitive sharpness. As men age, testosterone production declines at an average rate of roughly one to two percent per year after age thirty, and some men cross into clinically deficient territory where these systems begin to degrade measurably. The overlap between symptoms of aging and symptoms of low testosterone makes this a topic of significant interest in longevity medicine.

From a healthspan perspective, the downstream effects of chronic low testosterone are substantial. Sarcopenia (age-related muscle loss), increased visceral adiposity, reduced insulin sensitivity, declining bone density, and persistent fatigue can all be traced in part to insufficient androgenic signaling. Restoring testosterone to adequate levels in truly deficient individuals can address multiple aging-related trajectories simultaneously, which is why TRT occupies a central place in discussions about men's health optimization and biological aging.

Testosterone is a steroid hormone synthesized primarily in the Leydig cells of the testes, under the direction of luteinizing hormone (LH) from the anterior pituitary, which is in turn controlled by gonadotropin-releasing hormone (GnRH) from the hypothalamus. This feedback loop, the hypothalamic-pituitary-gonadal (HPG) axis, calibrates production based on circulating testosterone levels. When exogenous testosterone is introduced, the hypothalamus detects adequate or elevated levels and reduces GnRH output, which suppresses LH and FSH secretion and effectively shuts down endogenous production.

At the tissue level, testosterone enters target cells and either acts directly through the androgen receptor or is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, which binds the same receptor with greater affinity. In muscle, androgen receptor activation stimulates protein synthesis pathways, particularly through mTOR signaling, supporting hypertrophy and maintenance of lean tissue. In bone, testosterone (partly through aromatization to estradiol) promotes osteoblast activity and inhibits osteoclast resorption. In the brain, androgen receptors in the hippocampus, amygdala, and prefrontal cortex mediate effects on mood, spatial cognition, and motivation.

Different delivery methods produce different pharmacokinetic profiles. Intramuscular injections of testosterone cypionate or enanthate create a peak within one to three days followed by a gradual decline over one to two weeks, producing hormonal fluctuation that some men perceive as mood and energy swings. Transdermal gels provide more stable daily levels but require consistent application and carry a risk of transference to close contacts. Subcutaneous pellets, implanted every three to six months, deliver a slow, steady release but require a minor procedure. The choice of delivery method affects compliance, side effect profile, and the degree of hormonal stability achieved.

The initial visit typically involves a detailed symptom history, physical examination, and comprehensive blood work. If results confirm hypogonadism, the clinician will discuss delivery method options, each with trade-offs in convenience, cost, and hormonal stability. Once therapy begins, most men notice improvements in energy and libido within the first three to six weeks. Body composition changes, including measurable shifts in lean mass and fat mass, generally require three to six months to become apparent.

Follow-up appointments at approximately six weeks after initiation involve repeat blood work to assess testosterone trough levels, hematocrit, estradiol, and liver function. Dose adjustments are common during this titration phase. Some men experience initial side effects such as acne, mild fluid retention, or mood shifts as the body adjusts to a new hormonal baseline. These often resolve with dosing refinements. Once stable, monitoring intervals typically extend to every three to six months, with an annual comprehensive panel including PSA and lipids.

Injection frequency depends on the ester used. Testosterone cypionate and enanthate are commonly administered once or twice per week to maintain stable serum levels and minimize peaks and troughs. Some protocols use every-other-day subcutaneous microdoses for even smoother pharmacokinetics. Transdermal gels are applied daily. Subcutaneous pellets are implanted every three to six months.

TRT is generally an ongoing, indefinite commitment. Because exogenous testosterone suppresses the HPG axis, discontinuation leads to a period of very low testosterone until endogenous production resumes, which can take weeks to many months and may not fully recover in all men, particularly those who have been on therapy for years. For this reason, TRT should be viewed as a long-term therapeutic relationship rather than a short-term intervention. Men who wish to discontinue are typically tapered off under medical supervision, sometimes with the support of clomiphene citrate or hCG to stimulate recovery of the HPG axis.

The cost of TRT varies considerably depending on delivery method, whether insurance covers the therapy, and whether care is obtained through a conventional endocrinologist, a men's health clinic, or a telemedicine platform. Generic testosterone cypionate for injection is relatively inexpensive: typically $30 to $90 per month for the medication itself. Brand-name gels and patches range from $200 to $500 per month without insurance. Subcutaneous pellet insertion costs $500 to $1,500 per procedure, repeated two to three times per year.

Beyond medication, ongoing costs include blood work (which may run $100 to $400 per panel if not covered by insurance), office visits, and any ancillary medications such as hCG or aromatase inhibitors. Telemedicine TRT platforms have emerged with bundled monthly pricing, typically $100 to $250 per month inclusive of medication, supplies, and basic monitoring. Total annual out-of-pocket cost ranges from roughly $500 at the low end (generic injections with insured labs) to $4,000 or more for premium concierge-style management.

The evidence base for TRT in men with confirmed hypogonadism is substantial. Multiple randomized controlled trials, including the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in older men with low testosterone, demonstrated measurable improvements in sexual function, physical activity, mood, and bone density over twelve months. Body composition changes (increased lean mass, decreased fat mass) have been replicated across numerous trials. Effects on cognitive function have been less consistent, with some studies showing improvements in spatial memory or verbal fluency and others finding no significant benefit.

The cardiovascular safety profile has been the most debated area. An earlier retrospective study and a prematurely halted trial raised concerns about increased cardiovascular events, but a large randomized placebo-controlled trial (the TRAVERSE trial, enrolling over 5,000 men with cardiovascular risk factors) reported no statistically significant increase in major adverse cardiovascular events over a median follow-up period. However, an increase in certain secondary cardiovascular endpoints was observed. Erythrocytosis remains a well-documented risk that requires monitoring. Long-term data beyond five to ten years of continuous use are still limited, and the effects of TRT in men with borderline-low levels (as opposed to frank hypogonadism) are less well characterized.

TRT suppresses endogenous testosterone production and spermatogenesis, which can impair or eliminate fertility for the duration of therapy and sometimes beyond. Erythrocytosis is common and requires regular hematocrit monitoring; if levels exceed approximately 54%, therapeutic phlebotomy or dose reduction is typically recommended. Estradiol elevation through aromatization can cause gynecomastia, water retention, and mood disturbance, sometimes necessitating aromatase inhibitor co-administration. Acne, oily skin, and acceleration of male-pattern baldness occur in susceptible individuals. PSA should be monitored because, while TRT does not appear to cause prostate cancer, it may accelerate growth of pre-existing occult disease. Obstructive sleep apnea may worsen. Abrupt discontinuation can produce a period of severe hypogonadism before the HPG axis recovers, which may take months. Individuals considering TRT should have a thorough evaluation by a clinician experienced in hormone management.